When Will Retatrutide Be Available? FDA Timeline 2026-2028

The TRIUMPH-4 result that changed everything

In December 2025, Eli Lilly reported the first Phase 3 result for retatrutide: an average 28.7% body weight reduction at the 12 mg weekly dose over 68 weeks, in adults with obesity and knee osteoarthritis. That number is the highest weight loss percentage ever recorded for a GLP-1-class compound in Phase 3 trials.

For context:

• Semaglutide STEP 1 (Wilding 2021): -14.9% body weight at 68 weeks
• Tirzepatide SURMOUNT-1 (Jastreboff 2022): -22.5% at 72 weeks (15 mg dose)
• Retatrutide TRIUMPH-4 (Dec 2025): -28.7% at 68 weeks (12 mg dose)

That's not a marginal improvement — it's surgery-level results from a weekly injection. And TRIUMPH-4 was the smallest of the seven Phase 3 trials Eli Lilly is running. Six more are expected to report in 2026, and analysts at Citi project TRIUMPH-1 (the obesity primary trial) could exceed 30% weight loss due to its longer 80-week duration.

So when can you actually get this drug? That's where it gets complicated.

The timeline, milestone by milestone

Drug approval is not arbitrary — it follows a defined regulatory pathway with predictable timeframes. Based on Eli Lilly's disclosed Phase 3 schedule, FDA Prescription Drug User Fee Act (PDUFA) review windows, and standard manufacturing scale-up timelines:

The seven TRIUMPH trials — what's still pending

TRIUMPH-4 was just one piece. Eli Lilly is running seven Phase 3 trials simultaneously to support a comprehensive label that goes well beyond simple weight loss:

1. TRIUMPH-1 (obesity, primary efficacy) — 80 weeks, expected to read out in 2026. Citi analysts project ≥30% weight loss given the longer duration.
2. TRIUMPH-2 (obesity, longer-term safety) — readout expected 2026.
3. TRIUMPH-3 (type 2 diabetes) — readout expected 2026.
4. TRIUMPH-4 ✅ complete (obesity + knee osteoarthritis) — 28.7% weight loss + 75.8% reduction in WOMAC pain scores.
5. TRIUMPH-5 (sleep apnea) — readout expected 2026.
6. TRIUMPH-MASH (metabolic dysfunction-associated steatotic liver disease) — readout expected 2026.
7. TRIUMPH-CVOT (cardiovascular outcomes trial) — runs longer; readout expected late 2020s. This is the trial that would unlock cardiovascular-risk-reduction labeling, similar to what Wegovy has via the SELECT trial.

Eli Lilly does not need all seven trials to file the NDA. Combined data from TRIUMPH-1, TRIUMPH-2, and TRIUMPH-4 likely forms the efficacy core of the initial obesity submission. Other indications (T2D, OA, sleep apnea, MASH) can be added via supplemental NDA filings after initial approval.

Why the FDA review takes 10 months

Once the NDA is submitted, the FDA's Center for Drug Evaluation and Research (CDER) follows a defined process:

1. Filing review (60 days): Initial check that the application is complete and meets administrative requirements. Approximately 5-10% of filings are refused at this stage.
2. Substantive review (months 3-9): Multidisciplinary teams (medical, statistical, chemistry/manufacturing/controls, clinical pharmacology) evaluate the data. Advisory committee meetings may be convened for novel mechanisms — possible for the first triple agonist.
3. Risk Evaluation and Mitigation Strategy (REMS) discussion: Given the magnitude of weight loss and elevated discontinuation rates at higher doses, REMS protocols may be required.
4. PDUFA decision (month 10): Approval, complete response letter (CRL — typically requesting more data), or rejection.

Priority Review (6 months) is granted for drugs offering "significant improvement" over existing treatments. Retatrutide's 28.7% weight loss likely qualifies under FDA criteria, but Priority Review designation is a Lilly request to be made at submission. If granted, it could shave 4 months off — potentially moving approval from late 2027 to mid-2027.

Comparison: how long did tirzepatide take?

Tirzepatide (Mounjaro/Zepbound) is the closest analog for predicting retatrutide's timeline:

• Phase 3 SURPASS program started: 2018
• NDA filed (T2D): 2021
• FDA approved (Mounjaro for T2D): May 2022
• NDA filed (obesity): 2022
• FDA approved (Zepbound for obesity): November 2023
• Time from Phase 3 start to first FDA approval: ~3 years
• Stable supply (no shortage): late 2023 onward

Retatrutide started Phase 3 in 2024 (TRIUMPH program). Following the tirzepatide pattern of approximately 3 years from Phase 3 to first FDA approval places retatrutide approval in mid-2027 to late 2027. Add 2-4 months for manufacturing scale-up: early 2028 commercial availability is the realistic projection.

What could delay it

Drug development is never linear. Possible reasons for delay:

• Phase 3 safety signals. If TRIUMPH-1 or TRIUMPH-2 reveals unexpected adverse events, FDA may require additional trials. Higher GI side effect rates and discontinuations at the 12 mg dose are already documented.
• FDA Complete Response Letter (CRL). A CRL would require additional data submission and add 6-12 months. Approximately 30% of NDAs receive a CRL on first submission.
• Manufacturing capacity issues. Even after approval, Eli Lilly must scale GMP production. Tirzepatide had documented shortages for over a year post-approval.
• FDA enforcement environment. The 2026 FDA crackdown on compounded GLP-1 marketing could spill over into stricter requirements for new approvals — Lilly may need additional risk mitigation programs.
• Cardiovascular outcomes data delay. Although not required for initial approval, payers may demand TRIUMPH-CVOT readout before broad reimbursement coverage.

Why retatrutide may outperform expectations

Three reasons the realistic timeline could move faster than the projection above:

1. The 28.7% TRIUMPH-4 number exceeded most analyst projections. Phase 2 had shown 24.2% (Jastreboff 2023, NEJM^[1]). The Phase 3 result coming in significantly higher signals exceptional drug effect — this strengthens the case for Priority Review.
2. Eli Lilly has aggressive regulatory strategy experience. Mounjaro received FDA approval in 26 months from NDA filing. If Lilly executes similar speed for retatrutide, mid-2027 approval is feasible.
3. Demand pressure on FDA is unprecedented. Obesity is now classified as a chronic disease by the AMA and CMS reimbursement pathways are widening. FDA has incentive to approve effective new options quickly.

GlobalData (parent of Clinical Trials Arena) projects 2031 retatrutide sales of $15.6 billion based on a 2027 approval. That projection assumes the timeline lays out as expected.

What to do during the 18-24 month wait

If you're reading this article hoping to start treatment now, you have three legitimate options:

Option 1: Start tirzepatide (closest match to retatrutide)

Tirzepatide delivers 22.5% weight loss per SURMOUNT-1^[2] — about 6 percentage points less than retatrutide's TRIUMPH-4 result, but still substantially more than semaglutide. It's FDA-approved as Zepbound for weight management. If you want the closest analog to retatrutide that's available today, this is it.

👉 See our review of telehealth providers offering tirzepatide →

Option 2: Start FDA-approved semaglutide (Wegovy)

Semaglutide delivers 14.9% weight loss per STEP 1^[3]. Lower magnitude but established safety record (5+ years of post-market data) and a milder GI side-effect profile. Best for users who prioritize safety over maximum weight loss. Available branded as Wegovy or as Ozempic for diabetes.

Option 3: Compounded options (with regulatory caveats)

Compounded semaglutide and tirzepatide via licensed 503A pharmacies cost 75-90% less than branded versions ($115-249/month vs $1,000-1,300/month). The active ingredient is identical to branded versions, but the products are not FDA-approved as finished products. The 2026 FDA enforcement environment increases regulatory risk on this pathway — choose providers with clean records.

👉 Compare 8 compounded GLP-1 telehealth providers →

When NOT to take "shortcuts"

Multiple online vendors today claim to sell "retatrutide" research peptides. Avoid all of them. Reasons:

• Illegality. Retatrutide has no approved manufacturing pathway. Anyone producing it for human consumption is operating outside any regulatory framework.
• No quality control. Without FDA-approved GMP manufacturing, you have no guarantee of purity, potency, sterility, or actual content. Independent testing has found research peptides contaminated with bacteria, mycotoxins, and incorrect compounds.
• No physician oversight. Retatrutide doses peak at 12 mg weekly — that's a 12x escalation pattern that requires medical supervision. GI side effect rates increased significantly between 9 mg and 12 mg in trials.
• Legal exposure. Importing investigational drugs for personal use is restricted by FDA regulation. Telehealth providers cannot legally write prescriptions for non-approved compounds outside of registered clinical trials.

The only legitimate way to access retatrutide today is enrollment in an active TRIUMPH clinical trial. Eligibility and enrollment information is available at ClinicalTrials.gov by searching "retatrutide" or "TRIUMPH."

Frequently asked questions

Sources & references

1. [1] Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. DOI: 10.1056/NEJMoa2301972
2. [2] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038
3. [3] Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
4. [4] Madsbad S, Holst JJ. The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. Expert Opin Investig Drugs. 2025. DOI: 10.1080/13543784.2025.2472408
5. [5] Eli Lilly Investor Communications. TRIUMPH-4 Phase 3 trial results press release, December 2025. Lilly's triple agonist retatrutide delivered weight loss of up to an average of 71.2 lbs (28.7% body weight) in adults with obesity and knee osteoarthritis.
6. [6] FDA Center for Drug Evaluation and Research (CDER). Prescription Drug User Fee Act (PDUFA) Guidelines: Standard and Priority Review timelines.
7. [7] ClinicalTrials.gov. TRIUMPH Phase 3 program — search "retatrutide" or "LY3437943" for active trial enrollment.
8. [8] GlobalData / Clinical Trials Arena. Retatrutide market projection — $15.6B in 2031 sales (assumes 2027 FDA approval).

Disclaimers

FTC Affiliate Disclosure: This article contains affiliate links to telehealth providers offering FDA-approved alternatives (semaglutide, tirzepatide). If you sign up through these links, we may receive commission at no additional cost to you. This does not affect our editorial assessment. Retatrutide-related content has no affiliate relationships — there are no legitimate providers selling retatrutide as of May 2026.

Medical Disclaimer: Educational content only. Not medical advice. Always consult a licensed healthcare provider before starting, changing, or stopping any medication. Retatrutide is investigational and not FDA-approved as of May 2026 — do not use products claiming to be retatrutide outside of registered clinical trials. Information accurate as of May 4, 2026; this page is updated as new TRIUMPH program data is released.